- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03574571
A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer
Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Michael Morris, MD
- Phone Number: 646-422-4469
- Email: morrism@mskcc.org
Study Contact Backup
- Name: Josef Fox, MD
- Phone Number: 212-639-7371
Study Locations
-
-
State Of São Paulo
-
São Paulo, State Of São Paulo, Brazil
- Recruiting
- Instituto Brasileiro de Controle do Câncer/IBCC
-
Contact:
- Felipe Jose Silva Melo Cruz, MD
- Phone Number: (11) 3474-4222
- Email: felipe.cruz@hospitalsaocamilosp.br
-
-
-
-
-
Alkmaar, Netherlands, 1815
- Recruiting
- Noordwest Ziekenhuisgrouep Alkmaar (NWZ)
-
Contact:
- M. Hendriks, MD
- Phone Number: +31 72 5482872
-
Almelo, Netherlands, 7609
- Recruiting
- Ziekenhuisgroep Twente (ZGT)
-
Contact:
- I.M. Oving, MD
- Phone Number: +31-887083782
- Email: researchoncologie@zgt.nl
-
Breda, Netherlands, 4818
- Recruiting
- Amphia Hospital
-
Contact:
- H.M. Westgeet, MD
- Email: researchoncologie@amphia.nl
-
Den Haag, Netherlands, 2512
- Recruiting
- Haaglanden Medical Center
-
Contact:
- H Helgason, MD
- Email: h.helgason@haaglandenmc.nl
-
Deventer, Netherlands
- Recruiting
- Deventer Ziekenhuis
-
Contact:
- A.L.T. Imholz, MD
- Email: a.imholz@dz.nl
-
Hilversum, Netherlands, 1213
- Recruiting
- Tergooi Hospital
-
Contact:
- H.P. van den Berg, MD
- Phone Number: +31-887535153
- Email: Researchinterne@tergooi.nl
-
Nijmegen, Netherlands, 6532
- Recruiting
- Canisius Wilhelmina Ziekenhuis (CWZ)
-
Contact:
- D.M. Somford, MD
- Email: researchurologie@cwz.nl
-
Rotterdam, Netherlands, 3015 GD
- Recruiting
- Erasmus MC Cancer Institute
-
Contact:
- Ronald de Wit, MD, PhD
- Phone Number: +31-107040704
- Email: interne.oncologie@erasmusmc.nl
-
Rotterdam, Netherlands, 3045
- Recruiting
- Franciscus Gasthuis & Vlietland
-
Contact:
- P. Hamberg, MD
- Phone Number: +31-104616295
- Email: oncologietrials@franciscus.nl
-
Rotterdam, Netherlands, 3079
- Recruiting
- Maasstad Hospital
-
Contact:
- B.C.M. Haberkom, MD
- Phone Number: +31-102911911
- Email: reson@maasstadziekenhuis.nl
-
Utrecht, Netherlands
- Recruiting
- St. Antonius Ziekenhuis (Utrecht)
-
Contact:
- Cornelis Hunting, MD
- Email: j.hunting@antoniusaiekenhuis.nl
-
Zwolle, Netherlands, 8025
- Recruiting
- Isala Kliniek
-
Contact:
- Metin Tascilar, MD
- Email: m.tascilar@isala.nl
-
-
Plesmanlaan 121
-
Amsterdam, Plesmanlaan 121, Netherlands, 1066 CX
- Recruiting
- Nederlands Kanker Instituut (Data Collection Only)
-
Contact:
- Andre Bergman, MD
- Phone Number: +31 20 512 2046
-
-
-
-
-
Barcelona, Spain, 08003
- Recruiting
- Hospital Del Mar (Data Collection Only)
-
Contact:
- Alejo Rodriguez-Vida, MD, PhD
-
Barcelona, Spain, 08035
- Recruiting
- Vall d'Hebron Institute of Oncology (VHIO) (Data Collection Only)
-
Contact:
- Macarena Gonzalez, MD
- Phone Number: 34 934 89 30 00
-
Madrid, Spain, 28041
- Recruiting
- Hospital Universitario 12 de Octubre (Data Collection Only)
-
Contact:
- David Olmos, MBBS, MSc, PhD
- Phone Number: +34 913 90 80 00
-
Sevilla, Spain
- Recruiting
- HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO (Data Collection Only)
-
Contact:
- Begona Perez-Valderrama, MD
- Phone Number: 0034 955 013 068
-
Valencia, Spain
- Recruiting
- Instituto Valenciano de Oncología (Data Collection Only)
-
Contact:
- María José Juan-Fita, MD, PhD
- Phone Number: +34 961 11 40 00
-
-
Community Of Madrid
-
Madrid, Community Of Madrid, Spain, 28034
- Recruiting
- Ramón y Cajal Hospital
-
Contact:
- Teresa Alonso-Gordoa, MD
- Phone Number: +34 913 36 80 00
-
-
-
-
Arizona
-
Gilbert, Arizona, United States, 85234
- Completed
- Banner MD Anderson Cancer Center
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- Recruiting
- Yale University- Yale Cancer Center
-
Contact:
- Michael Hurwitz, MD, MPH, MsC
- Phone Number: 877-925-3637
- Email: Michael.hurwitz@yale.edu
-
-
Delaware
-
Newark, Delaware, United States, 19713
- Recruiting
- Helen Graham Cancer Center (Christiana Care)
-
Contact:
- Jamal Misleh, MD
- Email: jmisleh@cbg.org
-
-
Florida
-
Boca Raton, Florida, United States, 33486
- Recruiting
- Boca Raton Regional Hospital
-
Contact:
- Alan Koletsky, MD
- Phone Number: 561-955-6400
-
Miami, Florida, United States, 33140
- Recruiting
- Mount Sinai Medical Center (Miami)
-
Contact:
- Mike Cusnir, MD
- Phone Number: 305-535-3300
- Email: Mike.Cusnir@msmc.com
-
-
Illinois
-
Chicago, Illinois, United States, 606012
- Recruiting
- Rush University Medical Center
-
Contact:
- Dian Wang, MD, PhD
- Phone Number: 312-942-5751
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Recruiting
- Indiana University
-
Contact:
- Nabil Adra, MD
- Phone Number: 317-944-5349
- Email: nadra@iu.edu
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70121
- Recruiting
- Ochsner Cancer Institute
-
Contact:
- Marc Matrana, MD
- Phone Number: 504-842-3910
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- Recruiting
- University of Maryland Medical Center
-
Contact:
- Arif Hussain, MD
- Phone Number: 410-328-7225
-
-
Massachusetts
-
Worcester, Massachusetts, United States, 01655
- Recruiting
- University of Massachusetts
-
Contact:
- Kriti Mittal, MD, MS
- Phone Number: 508-334-3550
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- Completed
- University of Michigan Cancer Center
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- Recruiting
- University of Minnesota
-
Contact:
- Gautam Jha, MD
- Phone Number: 612-884-0600
-
-
Nebraska
-
Omaha, Nebraska, United States, 68114
- Recruiting
- Nebraska Cancer Specialists
-
Contact:
- Ralph Hauke, MD, FACP
- Phone Number: 402-354-8124
-
Omaha, Nebraska, United States, 68130
- Active, not recruiting
- XCancer Omaha / Urology Cancer Center
-
-
Nevada
-
Las Vegas, Nevada, United States, 89128
- Recruiting
- Comprehensive Cancer Centers of Nevada
-
Contact:
- Restituto Tibayan, MD
- Email: restituto.tibayan@usoncology.com
-
-
New Jersey
-
Basking Ridge, New Jersey, United States, 07920
- Recruiting
- Memorial Sloan Kettering Basking Ridge
-
Contact:
- Michael Morris, MD
- Phone Number: 646-422-4469
-
Camden, New Jersey, United States, 08103
- Completed
- MD Anderson Cancer Center at Cooper
-
Middletown, New Jersey, United States, 07748
- Recruiting
- Memorial Sloan Kettering Monmouth
-
Contact:
- Michael Morris, MD
- Phone Number: 646-422-4469
-
Montvale, New Jersey, United States, 07645
- Recruiting
- Memorial Sloan Kettering Bergen
-
Contact:
- Michael Morris, MD
- Phone Number: 646-422-4469
-
Saddle Brook, New Jersey, United States, 07663
- Recruiting
- New Jersey Urology
-
Contact:
- Elan Diamond, MD
- Phone Number: 973-873-7029
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87109
- Recruiting
- New Mexico Oncology and Hematology
-
Contact:
- Gregg Franklin, MD
- Email: greggef@nmohc.com
-
-
New York
-
Buffalo, New York, United States, 14203
- Recruiting
- University of Buffalo
-
Contact:
- Roberto Pili, MD
- Phone Number: 716-898-4328
-
Buffalo, New York, United States, 14263-0001
- Completed
- Roswell Park Cancer Institute
-
Commack, New York, United States, 11725
- Recruiting
- Memorial Sloan Kettering Commack
-
Contact:
- Michael Morris, MD
- Phone Number: 646-422-4469
-
Harrison, New York, United States, 10604
- Recruiting
- Memorial Sloan Kettering Westchester
-
Contact:
- Michael Morris, MD
- Phone Number: 646-422-4469
-
New York, New York, United States, 10065
- Recruiting
- Memorial Sloan Kettering Cancer Center
-
Contact:
- Josef Fox, MD
- Phone Number: 212-639-7371
-
Contact:
- Michael Morris, MD
- Phone Number: 646-422-4469
-
Principal Investigator:
- Michael Morris, MD
-
New York, New York, United States, 10065
- Recruiting
- New York Presbyterian Hospital-Weill Medical College of Cornell University
-
Contact:
- Scott Tagawa, MD
- Phone Number: 646-962-2072
-
New York, New York, United States, 10468
- Recruiting
- Bronx VA Hospital
-
Contact:
- Antonio Fojo, MD, PhD
- Phone Number: 6669 718-584-9000
-
Rochester, New York, United States, 14642
- Recruiting
- University of Rochester Medical Center
-
Contact:
- Chunkit Fung, MD
- Phone Number: 585-275-5823
-
Rockville Centre, New York, United States, 11570
- Recruiting
- Memorial Sloan Kettering Rockville Centre
-
Contact:
- Michael Morris, MD
- Phone Number: 646-422-4469
-
Uniondale, New York, United States, 11553
- Recruiting
- Memorial Sloan Kettering Nassau
-
Contact:
- Michael Morris, MD
- Phone Number: 646-422-4469
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27514
- Recruiting
- University of North Carolina
-
Contact:
- Young Whang, MD, PhD
- Phone Number: 984-974-0000
-
Monroe, North Carolina, United States, 28112
- Recruiting
- Atrium Health/ Levine Cancer Institute
-
Contact:
- Earle Burgess, MD
- Email: Earle.Burgess@atriumhealth.org
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- Recruiting
- University of Cincinnati Medical Center
-
Contact:
- Robert Franklin, MD
- Email: franklro@ucmail.uc.edu
-
Kettering, Ohio, United States, 45409
- Active, not recruiting
- Dayton Physicians Network
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- Recruiting
- University of Oklahoma
-
Contact:
- Adanma Ayanambakkam, MD
- Email: adanma-ayanambakkam@ouhsc.edu
-
-
Pennsylvania
-
Bala-Cynwyd, Pennsylvania, United States, 19004
- Recruiting
- MidLantic Urology
-
Contact:
- Laurence Belkoff, DO
- Phone Number: 610-667-3020
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Recruiting
- Medical University of South Carolina
-
Contact:
- Toros Dincman, MD
- Email: Dincmant@musc.edu
-
-
Texas
-
Houston, Texas, United States, 77090
- Recruiting
- Millennium Physicians
-
Contact:
- Umang Patel, MD
- Phone Number: 281-440-5006
-
Houston, Texas, United States, 77030
- Active, not recruiting
- Houston Methodist Research Institute
-
-
Washington
-
Seattle, Washington, United States, 98109
- Completed
- University of Washington
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Willing and able to provide written informed consent (ICF) and HIPAA authorization for the release of personal health information. A signed informed consent must be obtained before screening procedures are performed.
NOTE: HIPAA authorization may be either included in the informed consent or obtained separately.
- Males 18 years of age and above
- Histological or cytological proof of prostate cancer
Documented progressive mCRPC based on at least one of the following criteria:
- PSA progression defined as 25% increase over baseline value with an increase in the absolute value of at least 1.0 ng/mL that is confirmed by another PSA level with a minimum of a 1 week interval and a minimum PSA of 1.0 ng/mL.
- Soft-tissue progression defined as an increase ≥ 20% in the sum of the LD of all target lesions based on the smallest sum LD since treatment started or the appearance of one or more new lesions.
- Progression of bone disease (evaluable disease) or two or more new bone lesions by bone scan.
- Two or more bone lesions
- ECOG 0- 1
Normal organ function with acceptable initial laboratory values within 14 days of randomization:
- Albumin > 30 g/L
- ANC ≥ 1.5 x 10^9/L
- Hemoglobin ≥ 10 g/dL
- Platelet count ≥ 100 x 10^9/L
- Creatinine ≤ 1.5 x the institutional upper limit of normal (ULN)
- Bilirubin ≤ ULN (unless documented Gilbert's disease)
- SGOT (AST) ≤ 1.5 x ULN
- SGPT (ALT) ≤ 1.5 x ULN
- WBC count ≥ 3 x 10^9/L
- Subjects must agree to use a medically acceptable method of birth control (e.g., spermicide in conjunction with a barrier such as a condom) or sexual abstinence for the duration of the study, including 30 days after the last dose of study drug. Sperm donation is prohibited during the study and for 30 days after the last dose of study drug. Female partners must use hormonal or barrier contraception unless postmenopausal or abstinent.
- Serum testosterone < 50 ng/dL. Subjects must continue primary androgen deprivation with an LHRH analogue (agonist or antagonist) if they have not undergone orchiectomy.
- All acute toxic effects of any prior treatment have resolved to NCI-CTCAE v4.0 Grade 1 or less.
- Willing and able to comply with the protocol, including follow-up visits and examinations
Exclusion Criteria:
- Received any other investigational therapeutic agents or other anticancer therapies within 4 weeks prior to randomization.
- Received external beam radiotherapy within the 4 weeks prior to randomization.
- Has an immediate need for external beam radiotherapy.
- Has received any systemic bone-seeking radiopharmaceutical in the past.
- Has received any prostate cancer directed chemotherapy in the castration resistant setting. Subjects who have received up to 6 prior doses of docetaxel in the castration sensitive setting are permitted if they have not experienced disease progression within 36 weeks of last treatment with docetaxel.
Has received four or more systemic anticancer regimens for mCRPC.
- Treatment with docetaxel or abiraterone for non-castrate metastatic disease is permissible and does not count towards the lines of therapy for mCRPC
- A 'line' is a regimen. Combinations of hormones and other types of therapies count as single lines.
- Has known Grade ≥3 docetaxel-related toxicities or docetaxel toxicity related dose interruption or discontinuation.
- Has received blood transfusions or growth factors within the last 4 weeks prior to randomization.
- Symptomatic nodal disease (i.e., scrotal, penile, or leg edema).
- Has visceral metastases with ≥ 3 lung and/or liver metastases or individual lesion ≥2 cm, as assessed by CT scan or MRI of the chest/abdomen/pelvis within the last 8 weeks prior to randomization.
- Symptomatic loco-regional disease that causes ongoing Grade 3 or Grade 4 urinary or rectal symptoms.
- Subjects with a "currently active" second malignancy other than non-melanoma skin cancers or non-invasive bladder cancers or other in-situ or non-invasive malignancies. Subjects are not considered to have a "currently active" malignancy if they have completed therapy and are free of disease for ≥ 3 years.
- Has imminent or established cord compression based on clinical findings and/or MRI.
- Known bone marrow dysplasia
- Has received any of the following in the 4 weeks prior to randomization: 5-alpha-reductase inhibitors, herbal medications, natural hormonally active foods (e.g., phytoestrogens) or other food supplements known to alter PSA in humans
Any other serious illness or medical condition that would, in the opinion of the investigator, make this protocol unreasonably hazardous, including but not limited to:
- Uncontrolled infection
- NYHA III or IV heart failure
- Crohn's disease or those with ulcerative colitis who have not undergone a colectomy
- Known active infection with HIV, Hepatitis B or Hepatitis C
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Docetaxel
Docetaxel 75 mg/m2 will be administered IV every three weeks for 10 doses.
Prednisone will be given at a dose of 5mg orally twice daily.
|
Docetaxel 75 mg/m2 will be administered IV every three weeks for 10 doses.
|
Experimental: Docetaxel with Radium-223
Docetaxel 60 mg/m2 will be administered IV every 3 weeks for 10 doses.
Radium-223 will be administered at 55 kBq/kg, 6 injections at 6 weeks intervals.
|
Docetaxel 60 mg/m2 will be administered IV every 3 weeks for 10 doses.
Radium-223 will be administered at 55 kBq/kg, 6 injections at 6 weeks intervals.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival
Time Frame: 2 years
|
Overall survival is defined as the time from randomization to death from any cause.
|
2 years
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Michael Morris, MD, Memorial Sloan Kettering Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Genital Neoplasms, Male
- Prostatic Diseases
- Urogenital Diseases
- Male Urogenital Diseases
- Genital Diseases, Male
- Genital Diseases
- Prostatic Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Docetaxel
Other Study ID Numbers
- 18-150
- 2018-002944-10 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
University of Southern CaliforniaNational Cancer Institute (NCI); SanofiTerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ryan Kohlbrenner, MDRadiological Society of North AmericaCompletedProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage...United States
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
University of California, IrvineCompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...United States
-
Barbara Ann Karmanos Cancer InstituteGenentech, Inc.CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
Clinical Trials on Docetaxel 75 mg/m2
-
AstraZenecaCompletedLocally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IVUnited States, Poland, France, Germany, Brazil, Hungary, Netherlands, Bulgaria
-
Jina Pharmaceuticals Inc.Lambda Therapeutic Research Ltd.; Intas Pharmaceuticals, Ltd.RecruitingTriple Negative Breast CancerUnited States, India
-
Spanish Oncology Genito-Urinary GroupApices Soluciones S.L.; Janssen, LPCompleted
-
Seoul National University HospitalCompleted
-
Cancer Institute and Hospital, Chinese Academy...Jiangsu HengRui Medicine Co., Ltd.Unknown
-
Zhejiang Hisun Pharmaceutical Co. Ltd.Unknown
-
Aileron Therapeutics, Inc.TerminatedPrevention of Chemotherapy-induced MyelosuppressionUnited States, Bosnia and Herzegovina, Serbia, Bulgaria
-
Italian Sarcoma GroupFrench Sarcoma Group; Grupo Espanol de Investigacion en SarcomasActive, not recruitingLocalized High-risk Soft Tissue Sarcomas of the Extremities and Trunk Wall in AdultsSpain, Italy
-
Chengdu Zenitar Biomedical Technology Co., LtdRecruitingStudy of Purinostat Mesylate for Injection in the Treatment of Diffuse Large B-cell Lymphoma (DLBCL)Diffuse Large B Cell Lymphoma,DLBCLChina
-
Bay Area Gynecology OncologyUnknownCervical Cancer | Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer | Uterine Cancer | Gastrointestinal Cancers | MesotheliomasUnited States